RLAY
Relay Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$18.35Close
$3.2BMarket cap
$6.05 – $20.7552-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 95 · stronger than 95% of stocks over 12 months
- Volume drying up last 10 days 29% under the 50-day average
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 0.9%
price change
1mo
up 1.7%
price change
12-month return
up 150%
market up 11% ·
its own up 140%
F-score
—
— Not assessed
Altman Z
30.22
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.6×
price / book
Earnings yield
down 9.7%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 53%
year on year
EPS growth
—
latest quarter
Sales growth
down 48%
latest quarter · +13 pts
ROE
down 41%
return on equity
Free cash margin
down 1536%
-$235.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-61% then +53%)
Trade setup
ATR%
5.4%
$0.98 a day · 2×ATR $16.38
RS
95 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.2×
vs 50-day average
Up/down volume
0.68
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.6% over the year, from 168m to 174m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 20260% vs market2 sessions after results
Financials
- Net -1801%
- Free cash -1536%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $82.7M | $3.0M | $1.4M | $25.5M | $10.0M | $15.4M |
| Operating income | -$55.8M | -$364.7M | -$299.3M | -$373.0M | -$372.5M | -$302.7M |
| Net income | -$52.4M | -$363.9M | -$290.5M | -$342.0M | -$337.7M | -$276.5M |
| Net margin | -63% | -12013% | -21036% | -1339% | -3375% | -1801% |
| Earnings per share | -$1.23 | -$3.82 | -$2.59 | -$2.79 | -$2.36 | -$1.61 |
| Free cash flow | -$104.4M | -$77.9M | -$238.6M | -$304.4M | -$251.1M | -$235.9M |
| Free cash margin | -126% | -2571% | -17274% | -1192% | -2509% | -1536% |
| Cash | $447.6M | $280.1M | $151.8M | $143.7M | $124.3M | $84.0M |
| Shareholders' equity | $763.3M | $897.8M | $950.2M | $752.0M | $777.8M | $567.1M |
| Shares outstanding | 89.91m | 108.21m | 121.11m | 127.46m | 167.76m | 173.87m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Material agreement · Results ↗ |
| Jun 9, 2026 | Charter or bylaws · Shareholder vote ↗ |
| May 21, 2026 | Material agreement ↗ |
| May 19, 2026 | Regulation FD · Other events ↗ |
| May 5, 2026 | Results ↗ |
| Apr 27, 2026 | Regulation FD · Other events ↗ |
| Mar 16, 2026 | Regulation FD · Other events ↗ |
| Mar 11, 2026 | Charter or bylaws ↗ |
| Feb 26, 2026 | Results ↗ |
| Feb 3, 2026 | Regulation FD · Other events ↗ |
| Nov 6, 2025 | Results · Director or officer change · Regulation FD ↗ |
| Aug 7, 2025 | Results ↗ |